|
|
|
Subscribe
|
|
|
Contact
|
|
|
New hopes, new therapies, and overcoming cell collection challenges
The new year is just weeks away, bringing new hopes and the opportunity to turn resolutions into reality. We’re feeling the excitement and are thrilled to see some hopes coming to life with innovative new therapies for sickle cell disease (SCD). In this issue of Access Point, we highlight those treatments in one article, where we help you overcome the challenges of cell collection from patients with SCD. You’ll also find guidelines and advice on other cell collection issues to help you get the most from your Spectra Optia™ Apheresis System and give your patients the best possible care.
|
|
|
|
Kids' Access to Care Act passes U.S. House
Children with life-threatening conditions — including blood cancers, blood disorders, and rare diseases — often must cross state lines to get treatment. But coordinating the process between healthcare providers in different states is challenging, particularly for patients enrolled in Medicaid or the Children’s Health Insurance Program (CHIP).
The Accelerating Kids’ Access to Care Act is designed to reduce delays in access to care by streamlining the process for out-of-state pediatric care providers to enroll in another state’s Medicaid program. On September 17, 2024, the Act unanimously passed the U.S. House of Representatives. It is currently awaiting action in the U.S. Senate. You can follow its progress and read the full text of the Act at Congress.gov.
|
|
|
|
|
|
Cell Collection Challenge 1
|
|
Six considerations for stem cell collections from patients with sickle cell disease
In 2023, the U.S. Food and Drug Administration (FDA) approved two cell-based gene therapies for SCD1 based on hematopoietic stem cell (HSC) transplantation. Both treatments — Casgevy and Lyfgenia — are considered curative.2 And both require collecting the patient’s own blood stem cells, a process made challenging due to the nature of sickled cells. Here, we explain why and highlight six considerations for the collection procedure.
|
Cell Collection Challenge 2
|
|
Five actions to assist with white blood cell collection using the continuous mononuclear cell procedure
HSC collection for patients with sickle cell disease isn’t the only protocol that presents particular clinical and procedural considerations. Other challenges can range from facility-specific factors to biospecimen or research provider requirements to protocol-specific policies. In this article, we zero in on using the continuous mononuclear cell collection (CMNC) procedure to collect white blood cells (WBCs). Read on for guidelines that can help smooth this process.
|
|
|
|
Dear Access Point,
I’ve noticed that my collection efficiencies are dropping in my CMNC collections. What can be some causes of poor collection efficiency? — Amy in Kyle, Texas
Dear Amy,
A number of issues can impact collection efficiency during a CMNC procedure. Here are some common causes you can keep an eye on.
- Clumping can reduce collection efficiency by obstructing the collect port and disrupting the interface.
- Collection Preference (CP) affects the number and type of cells that flow through the collect port. It is important to choose an appropriate CP up front and monitor the color of contents in the collect line (compared to the Collection Preference tool color bar) throughout the procedure.
- Access alarms can reduce efficiency by creating pauses during the procedure.
- Collect pump flow rate for CMNC procedures defaults to 1 mL/minute unless the inlet pump flow rate is less than 20 mL/minute. However, you can adjust the rate during the procedure. For help identifying a collect pump flow rate to optimize efficiency, see the chart below.
|
|
|
|
|
|
If you have a specific question about the Spectra Optia system, let us know. We will feature a reader question in each Access Point edition. Be sure to tell us your first name, hometown, and state or province. Questions not featured will be answered directly via email.
|
|
|
|
|
|
|
|
> Guidelines for collecting autologous hematopoietic stem cells from patients with sickle cell disease
Get more insight on clinical and procedural considerations when using Spectra Optia for apheresis collection of HSCs from this patient population.
|
|
|
|
Did You Know?
Of those 76 patients, 44 were treated with Casgevy and 32 were treated with Lyfgenia. Both therapies are based on HSC transplant1 and are considered groundbreaking because they target the genetic cause of sickle cell disease. Casgevy uses genome editing while Lyfgenia introduces genetically modified stem cells to produce healthier red blood cells.1
|
|
|
|
Live From Lakewood
Spectra Optia Apheresis System Software Version 12.1 Overview | January 16 | 12 p.m. MT
|
|
|
|
|
|
You're on the front lines of care, and we're here to assist.
Contact us online or via 877.339.4228.
|
|
|
|
|
|
|
|
could help you make the most of your Spectra Optia system and your relationship with
Terumo Blood and Cell Technologies to do even more for your patients.
|
|
|
|
|
|
Spectra OptiaTM and ReveosTM are either registered trademarks or trademarks of Terumo BCT, Inc. in the United States and/or other countries.
|
|
|
|
©2024 Terumo BCT, Inc. | All Rights Reserved | TS-OPTI-02431 | TerumoBCT.com
|
|
|
|
|
